Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
12/2005
12/15/2005WO2005118630A2 Peptides for the treatment of diabetes
12/15/2005WO2005118629A1 BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS
12/15/2005WO2005118628A2 Nucleic acid molecules encoding plant cyclotide polypeptides and methods of use
12/15/2005WO2005118627A2 Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use
12/15/2005WO2005118626A2 Peptides for inducing a ctl and/or htl response to hepatitis c virus
12/15/2005WO2005118624A1 Peptides antagonists for inhibiting heat shock protein (hsp 16.3) of mycobacterium tuberculosis
12/15/2005WO2005118617A2 Method for the purification of polymers carrying a lipophilic group
12/15/2005WO2005118616A1 Preparation of solid phase bound peptides or pnas
12/15/2005WO2005118615A1 Inhibitors of regiii proteins as asthma therapeutics
12/15/2005WO2005118614A1 Methods and compositions for treating neuropathic pain
12/15/2005WO2005118611A2 Microutrophin and uses thereof
12/15/2005WO2005117994A2 Bmp pathway methods and compositions
12/15/2005WO2005117993A2 Method of using adenoviral vectors with improved safety and efficacy for the treatment of cancer
12/15/2005WO2005117989A1 Drugs for the prevention or treatment of immunodeficiencies, autoimmune diseases or for the induction of immune tolerance
12/15/2005WO2005117983A2 Carrier conjugates of tnf-peptides
12/15/2005WO2005117975A2 Methods for treating vascular disease
12/15/2005WO2005117964A2 Cynomolgus prostate specific antigen
12/15/2005WO2005117963A1 Medical uses of carrier conjugates of non-human tnf-peptides
12/15/2005WO2005117948A1 Method of stabilizing proteins
12/15/2005WO2005117945A1 Methods of using il-1 antagonists to treat autoinflammatory disease
12/15/2005WO2005117944A2 Hsp20 inhibits amyloidogenesis and neurotoxicity
12/15/2005WO2005117940A2 Cell death modulation via antagonists of fasl and fas activation
12/15/2005WO2005117936A2 Method for enhancing or inhibiting insulin-like growth factor-i
12/15/2005WO2005117935A1 Multiple agent therapy for sexual dysfunction
12/15/2005WO2005117577A2 Model for neurodegenerative disorders
12/15/2005WO2005117568A1 Plants having improved growth characteristics and a method for making the same
12/15/2005WO2005117557A2 Expression system
12/15/2005WO2005108560A3 Synthesis and purification of west nile virus virus-like particles
12/15/2005WO2005107785A3 Human complement c3 derivates with cobra venom factor-like function
12/15/2005WO2005099752A9 Antigen delivery vectors and constructs
12/15/2005WO2005099361A3 MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN
12/15/2005WO2005095446A8 Factor reca from bacillus licheniformis and reca-inactivated safety stems used for biotechnological production
12/15/2005WO2005083126A3 Alterations of fibulin genes in macular degeneration
12/15/2005WO2005083092A3 Transposon from aspergillus fumatigus and mutagenesis therewith
12/15/2005WO2005082934A3 Novel apo2l and il-24 polypeptides, polynucleotides, and methods of their use
12/15/2005WO2005082396A3 Use of mda-7 to inhibit infection by pathogenic organisms
12/15/2005WO2005080985A3 Methods and compositions for detecting and treating autoimmune diseases
12/15/2005WO2005079155A3 Photoreactive compound specifically binding to calcium binding proteins
12/15/2005WO2005070966A3 Fusion polypeptides capable of activating receptors
12/15/2005WO2005063809A8 Nature-identical erythropoietin
12/15/2005WO2005062767A3 Hoxd3, hoxa3, and hoxb3 compositions and methods for improved wound healing
12/15/2005WO2005060541A3 Peptides and methods for inducing cellular resistance to infection
12/15/2005WO2005058959A3 Treatment of viral infections
12/15/2005WO2005056572A3 Clustered multi-antigenic carbohydrate constructs, methods for their preparation and uses thereof
12/15/2005WO2005054485A3 Adenovirus-transfected primary cells and methods of pathway mapping
12/15/2005WO2005048914A3 Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
12/15/2005WO2005039501A3 Immunogenic composition and method of developing a vaccine based on fusion protein
12/15/2005WO2005038017A8 Prevention of incorporation of non-standard amino acids into protein
12/15/2005WO2005035576A3 Method of resisting osteoclast formation
12/15/2005WO2005033267A3 Antigens targeted by prevalent pathogenic t cells in type 1 diabetes and uses thereof
12/15/2005WO2005032582A8 Immunogenic compositions for streptococcus pyogenes
12/15/2005WO2005021556A3 Modified protease inhibitors
12/15/2005WO2005012359A3 Anti-vegf antibodies
12/15/2005WO2005005610A3 Mutant adeno-associated virus virions and methods of use thereof
12/15/2005WO2004104162A3 Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
12/15/2005WO2004096994A3 Genes upregulated in a tomato plant having an increased anthocyanin content phenotype
12/15/2005WO2004089072A9 Non-human mammals and animal cells containing a mutated alpha2/delta1 gene
12/15/2005WO2004079337A3 Voltage sensor domains of voltage-dependent ion channel proteins and uses thereof
12/15/2005WO2004064787A3 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
12/15/2005WO2004055050A9 Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
12/15/2005WO2004043403A3 Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
12/15/2005WO2004041842A3 Epitopes of hepatitis c virus
12/15/2005WO2004016229A3 Compositions and methods for treating rage-associated disorders
12/15/2005WO2004012588A3 Use of biomarkers for detecting ovarian cancer
12/15/2005WO2003089653A3 Human il-18 crystal structure
12/15/2005WO2003063759A3 Hsp peptides and analogs for modulation of immune responses via antigen presenting cells
12/15/2005WO2003062370A3 Multimeric proteins and methods of making and using same
12/15/2005WO2003027235A3 Afap sequences, polypeptides, antibodies and methods
12/15/2005WO2002083921A8 Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
12/15/2005WO2002083855A3 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
12/15/2005WO2002079225A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
12/15/2005US20050278808 Methods for imparting desirable phenotypic traits, including drought, freeze, and high salt tolerance and methods for increasing seed production
12/15/2005US20050278805 Method of increasing seed oil content in plants
12/15/2005US20050278801 Plastid transit peptides
12/15/2005US20050278797 Transgenic cell and gene recombinant animal having a mutant SDHC gene derived from mammals
12/15/2005US20050278796 FIAT nucleic acids and proteins and uses thereof
12/15/2005US20050277767 Novel human nuclear transporters and polynucleotides encoding the same
12/15/2005US20050277766 Udp-glucose aglycon-glucosytransferase
12/15/2005US20050277763 For cancer therapy
12/15/2005US20050277762 Semisynthetic protein-based site-directed probes for identification and inhibition of active sites, and methods therefor
12/15/2005US20050277761 Potassium channel interactors polypeptides and uses thereof
12/15/2005US20050277609 Immunostimulatory nucleic acid molecules
12/15/2005US20050277605 Superior molecular vaccine based on self-replicating rna, suicidal dna or naked dna vector, that links antigen with polypeptide that promotes antigen presentation
12/15/2005US20050277604 Immunostimulatory nucleic acid molecules
12/15/2005US20050277603 Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof
12/15/2005US20050277594 Polypeptide for the treatment of cancer and a method for preparation thereof
12/15/2005US20050277592 Beta-peptides
12/15/2005US20050277591 Use of RPL41 to treat infections and inhibit cancer
12/15/2005US20050277590 Includes substitutions/modifications which enhance secretion/degradation resistance; drugs; for insulin release and controlling blood glucose concentration
12/15/2005US20050277589 Linear cationic peptides having antibacterial and/or antifungal properties
12/15/2005US20050277588 Low white blood cell titer
12/15/2005US20050277587 CD7 as biomarker and therapeutic target for psoriasis
12/15/2005US20050277586 Peptide chemically modified with polyethylene glycol
12/15/2005US20050277580 Antidiabetic agents; lipophilic
12/15/2005US20050277193 Vectors and methods for gene transfer
12/15/2005US20050277192 Hepatitis C virus nonstructural protein 4A (NS4A) is an enhancer element
12/15/2005US20050277181 for increasing or decreasing binding of lysozyme polypeptide to Treponema pallidum P17 polypeptide (Tp17); immunoassay, ELISA
12/15/2005US20050277176 Human and mouse beta-defensins, antimicrobial peptides
12/15/2005US20050277174 Mutant tyrosine repressor, a gene encoding the same, and a method for producing L-DOPA
12/15/2005US20050277161 Phosphopeptide antigens associated with MHC molecules
1 ... 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 ... 2916